Fetal Valproate Syndrome

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Fetal Valproate Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • Dalpro, Fetal Effects From
  • Depakene, Fetal Effects From
  • Depakote Sprinkle, Fetal Effects From
  • Depakote, Fetal Effects From
  • Divalproex, Fetal Effects From
  • Epival, Fetal Effects From
  • Myproic Acid, Fetal Effects From
  • Valproic Acid, Fetal Effects From
  • Fetal Anti-Convulsive Syndrome

Disorder Subdivisions

  • None

General Discussion

Fetal Valproate Syndrome is a rare congenital disorder caused by exposure of the fetus to valproic acid (dalpro, depakene, depakote, depakote sprinkle, divalproex, epival, myproic acid) during the first three months of pregnancy. Valproic acid is an anticonvulsant drug used to control certain types of seizures in the treatment of epilepsy. A small percentage of pregnant women who take this medication can have a child with Fetal Valproate Syndrome. The exact prevalence of this condition remains to be established. Symptoms of this disorder may include spina bifida, distinctive facial features, and other musculoskeletal abnormalities.


Infants with Fetal Valproate Syndrome may be born with spina bifida. Spina bifida is the incomplete closure of bony spine. It occurs when the tube of tissue that lies along the center of the early embryo (neural tube) does not completely fuse during fetal growth. Part of the contents of the spinal canal may protrude through this opening (bifida cystica). Depending on the severity of the opening, a variety of neurological and physical symptoms may occur. (For more information on this disorder choose "Spina Bifida as your search term in the Rare Disease Database.)

Distinctive facial features are characteristic of Fetal Valproate Syndrome. Affected infants may have a vertical fold of skin on either side of the nose that forms a groove under the eye (epicanthal folds); a small, upturned nose with a flat bridge; a small mouth (microstomia); a long, thin, upper lip; a downturned mouth; and/or minor abnormalities of the ears.

Other abnormalities that may be found in a few affected individuals include: underdeveloped nails of the fingers and toes; dislocation of the hip; long, thin fingers and toes (arachnodactyly); overlapping fingers and toes; separation of the rectus muscle of the abdominal wall (diastasis recti); absence of the first rib; a condition in which the urinary opening is on the underside of the penis (hypospadias); abnormalities of the heart; softening of the windpipe (tracheomalacia); and/or a club foot.

Growth deficiency and an unusually small head (microcephaly) may also occur when valproic acid is taken in combination with other anticonvulsant drugs during pregnancy.


Fetal Valproate Syndrome is a rare disorder that may occur when a fetus is exposed to valproic acid (depakene, dalpro, myproic acid, depakote, depakote sprinkle, divalproex, epival) during the first three months of pregnancy. It is believed that valproic acid crosses the placenta and interferes with normal development causing developmental abnormalities in the fetus (teratogenesis). Some researchers feel that the severity of the defects caused by valproic acid may be dosage related while others have found no dose-related effect.

Valproic acid in combination with other anticonvulsant drugs may also cause fetal abnormalities.

Affected Populations

Fetal Valproate Syndrome affects males and females in equal numbers. Spina Bifida is found in approximately 1-5% of those exposed to valproic acid during fetal development. Facial abnormalities have been found in almost half of the children exposed to valproic acid in utero. There were approximately 175 cases of Fetal Valproate Syndrome reported internationally between 1974 and 1988.

Standard Therapies

Valproic acid has been reported to cause Fetal Valproate Syndrome in the unborn fetus when taken by the mother during the first three months of pregnancy. As a result, it is important to advise one's physician when a person taking seizure medications is considering pregnancy.

Mild cases of Spina Bifida may not require treatment. In moderate cases surgery may be considered. Surgery may prevent the worsening of the condition in some cases, but cannot restore the lost muscle function. In those extreme cases where the sac (meningocele) breaks or appears about to break, immediate surgery becomes essential. Individuals with severe Spina Bifida may develop contractures (shortening of the muscles) and abnormalities of posture. This is due to the paralysis of muscles in the legs. A child with Spina Bifida should have the necessary therapy (orthopedic and physical) beginning at an early age to prevent contractures. (For more information on this disorder choose "Spina Bifida" as your search term in the Rare Disease Database).

Surgery may be necessary to correct heart defects as well as other major malformations that may be present. Other treatment is symptomatic and supportive.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, contact:




Hersh JH. Fetal Valproate Syndrome. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:192-93.

Buyce ML. Editor-in-Chief. Birth Defects Encyclopedia. Blackwell Scientific Publications. Center for Birth Defects Information Services, Inc., Dover, MA; 1990:730.


Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet. 2001;98:168-75.


Witters I, Van Assche F, Fryns JP. Nuchal edema as the first sign of fetal valproate syndrome. Prenat Diagn. 2002;22:834-35.

Malm H, Kajantie E, Kivirikko S, et al. Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility. Neurology. 2002;59:630-33.

Glover SJ, Quinn AG, Barter P, et al. Ophthalmic findings in fetal anticonvulsive syndrome(s). Ophthalmology. 2002;109:942-47.

Lajeunie E, Barcik U, Thorne JA, et al. Craniosynostosis and fetal exposure to sodium valproate. J Neurosurg. 2001;95:778-82.

Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch Dis Child. 1993;69(3 Spec No):288-91.

Williams G, King J, Cunningham M, et al. Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol. 200;43:202-06.

Ardinger HH, Atkin JF, Blackston RD, et al. Verification of the fetal valproate phenotype. Am J Med Genet. 1988;29:171-85.


Multiple Congenital Anomaly/Mental Retardation (MCA/MR) Syndromes. nd. 3pp.


CDC. Valproate (valproic acid): A New Cause of Birth Defects. Page converted: 08/05/98:(1983) :2pp.


Turnpenny PD. Fetal Anti-Convulsant Syndrome. Contact a Family. Last Updated: November 2002:2pp.


Chemical Teratogens, Carcinogens, Mutagens. nd.


Pasquier S, Zeilinger G. Fetal valproate syndrome. Swiss Society of Neonatology. nd. 2pp.



Spina Bifida Association of America

4590 MacArthur Boulevard NW

Suite 250

Washington, DC 20007-4226

Tel: (202)944-3285

Fax: (202)944-3295

Tel: (800)621-3141

Email: sbaa@sbaa.org

Internet: http://www.sbaa.org

International Federation for Spina Bifida and Hydrocephalus

Cellebroersstraat 16

Brussels, B1000


Tel: 32025020413

Fax: 32025021129

Email: info@ifglobal.org

Internet: http://www.ifglobal.org

Spina Bifida and Hydrocephalus Canada

Suite 647-167 av. Lombard Avenue



R3B 0V3


Tel: 2049253650

Fax: 2049253654

Tel: 8005659488

Email: info@sbhac.ca

Internet: http://www.sbhac.ca

Organisation For Anti-Convulsant Syndrome

23 Morriston Close

South Oxhey

Watford, WD196UB

United Kingdom

Tel: 4402083869271

Email: OACSsecretary@gmail.com

Internet: http://www.oacscharity.org

Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.